Gain the Knowledge You Need to Successfully Trade Futures Markets
Our Technical Analysis Guide will give you the insight into today’s fast-moving markets. It’s designed to give you a head start in learning the basics of various TA tools and techniques.
pixel

NASDAQ:HOLX - Hologic Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $88.00
  • Forecasted Upside: 21.72 %
  • Number of Analysts: 13
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
$72.30
▲ +0.53 (0.74%)

This chart shows the closing price for HOLX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Hologic Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HOLX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HOLX

Analyst Price Target is $88.00
▲ +21.72% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Hologic in the last 3 months. The average price target is $88.00, with a high forecast of $110.00 and a low forecast of $77.00. The average price target represents a 21.72% upside from the last price of $72.30.

This chart shows the closing price for HOLX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
Learn How to Analyze Your Market and Trading Plan
Custom-design an options strategy to fit your market outlook. This guide goes beyond the basics to help you understand how to evaluate a strategy’s risk and reward. Start with your market outlook, then hone in on your strategy based on the risk you’re willing to take.
pixel

Current Consensus is Buy

The current consensus among 13 polled investment analysts is to buy stock in Hologic. This rating has held steady since October 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
1/31/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 0 sell ratings
4/30/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 6 hold ratings
  • 0 sell ratings
7/29/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
10/27/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
1/25/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/25/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/24/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/24/2021

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/6/2021Evercore ISIUpgradeIn-Line ➝ Outperform$78.00Low
4/30/2021Morgan StanleyLower Price TargetEqual Weight$84.00 ➝ $77.00Medium
4/29/2021CitigroupLower Price Target$90.00 ➝ $80.00Low
4/29/2021SVB LeerinkLower Price TargetOutperform$94.00 ➝ $85.00High
4/5/2021Jefferies Financial GroupBoost Price TargetBuy$106.00 ➝ $110.00Low
3/1/2021Robert W. BairdBoost Price TargetBuy$84.00 ➝ $91.00Low
2/22/2021Robert W. BairdReiterated RatingBuy$84.00 ➝ $91.00Low
2/22/2021BTIG ResearchBoost Price TargetBuy$84.00 ➝ $91.00Medium
1/28/2021Wells Fargo & CompanyBoost Price TargetOverweight$90.00 ➝ $95.00Medium
1/6/2021Raymond JamesReiterated RatingBuyN/A
12/15/2020Morgan StanleyBoost Price TargetEqual Weight$80.00 ➝ $84.00Low
12/8/2020ArgusBoost Price Target$85.00 ➝ $100.00Low
11/20/2020Needham & Company LLCDowngradeBuy ➝ HoldLow
11/9/2020Morgan StanleyBoost Price TargetEqual Weight$68.00 ➝ $80.00High
11/5/2020Jefferies Financial GroupBoost Price Target$80.00 ➝ $98.00Low
11/5/2020Smith Barney CitigroupBoost Price Target$90.00 ➝ $85.00Low
11/5/2020UBS GroupBoost Price TargetNeutral$77.00 ➝ $81.00Low
11/5/2020JPMorgan Chase & Co.Boost Price TargetOverweight$75.00 ➝ $85.00High
11/5/2020Wells Fargo & CompanyBoost Price TargetOverweight$80.00 ➝ $90.00High
11/5/2020Raymond JamesBoost Price TargetOutperform$75.00 ➝ $86.00Medium
11/5/2020SVB LeerinkBoost Price TargetOutperform$80.00 ➝ $94.00Low
11/5/2020Needham & Company LLCBoost Price TargetBuy$78.00 ➝ $88.00Medium
8/26/2020Needham & Company LLCReiterated RatingBuy$78.00Low
7/31/2020Morgan StanleyBoost Price TargetEqual Weight$55.00 ➝ $68.00Low
7/30/2020Wells Fargo & CompanyBoost Price TargetOverweight$63.00 ➝ $80.00High
7/30/2020Raymond JamesBoost Price TargetOutperform$68.00 ➝ $78.00High
7/30/2020CitigroupBoost Price TargetPositive ➝ Buy$63.00 ➝ $85.00Low
7/30/2020SVB LeerinkBoost Price TargetOutperform$66.00 ➝ $80.00Low
7/30/2020Needham & Company LLCBoost Price TargetBuy$64.00 ➝ $78.00Low
7/29/2020BTIG ResearchReiterated RatingBuy$63.00 ➝ $84.00Low
7/27/2020William BlairReiterated RatingOutperformLow
7/23/2020Raymond JamesBoost Price TargetOutperform$62.00 ➝ $68.00Low
7/15/2020SVB LeerinkBoost Price TargetOutperform$62.00 ➝ $66.00Low
7/1/2020Needham & Company LLCInitiated CoverageBuy$60.00 ➝ $64.00High
6/30/2020CowenUpgradeMarket Perform ➝ Outperform$64.00High
6/26/2020BTIG ResearchReiterated RatingBuy$60.00Low
6/16/2020BTIG ResearchBoost Price TargetBuy$54.00 ➝ $60.00Low
6/10/2020Needham & Company LLCReiterated RatingBuyLow
6/9/2020Morgan StanleyBoost Price TargetEqual Weight$53.00 ➝ $55.00Low
6/3/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$62.00Medium
6/2/2020Needham & Company LLCInitiated CoverageBuy$60.00High
4/30/2020JPMorgan Chase & Co.Boost Price TargetOverweight$45.00 ➝ $55.00High
4/30/2020Morgan StanleyBoost Price TargetEqual Weight$40.00 ➝ $53.00High
4/30/2020Wells Fargo & CompanyBoost Price TargetOverweight$48.00 ➝ $60.00High
4/30/2020BTIG ResearchBoost Price TargetBuy$46.00 ➝ $54.00High
4/30/2020SVB LeerinkUpgradeMarket Perform ➝ Outperform$41.00 ➝ $62.00High
4/30/2020Needham & Company LLCBoost Price TargetBuy$52.00 ➝ $60.00High
4/28/2020UBS GroupLower Price TargetNeutral$58.00 ➝ $52.00Low
4/19/2020Wells Fargo & CompanyUpgradeEqual Weight ➝ OverweightMedium
4/8/2020SVB LeerinkLower Price TargetMarket Perform$57.00 ➝ $41.00High
4/8/2020Stifel NicolausLower Price TargetHold$52.00 ➝ $45.00High
4/8/2020William BlairReiterated RatingOutperformHigh
4/7/2020BTIG ResearchReiterated RatingPositive ➝ Buy$54.00 ➝ $46.00Low
4/7/2020Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$48.00High
4/2/2020Needham & Company LLCUpgradeBuy$62.00 ➝ $52.00High
3/27/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$53.00 ➝ $40.00Low
3/26/2020BarclaysLower Price TargetEqual Weight$51.00 ➝ $43.00High
3/17/2020JPMorgan Chase & Co.Lower Price TargetOverweight$60.00 ➝ $50.00High
1/30/2020Piper SandlerBoost Price Target$58.00 ➝ $61.00Low
1/30/2020BTIG ResearchReiterated RatingBuy$54.00Medium
1/13/2020BarclaysBoost Price TargetEqual Weight$50.00 ➝ $51.00Low
1/13/2020Needham & Company LLCBoost Price TargetBuy$57.00 ➝ $62.00Low
1/7/2020Wells Fargo & CompanyInitiated CoverageEqual Weight$57.00Low
1/6/2020CitigroupInitiated CoverageBuy$60.00Low
1/2/2020Morgan StanleyDowngradeEqual Weight ➝ UnderweightLow
12/17/2019Morgan StanleyBoost Price TargetUnderweight$45.00 ➝ $50.00Low
12/13/2019Stifel NicolausBoost Price TargetHold$48.00 ➝ $52.00Low
11/21/2019William BlairReiterated RatingBuyLow
11/20/2019SVB LeerinkReiterated RatingHold$50.00Medium
9/26/2019Bank of AmericaUpgradeNeutral ➝ Buy$54.00 ➝ $59.00High
8/14/2019ArgusBoost Price TargetBuy$62.00High
8/5/2019Stifel NicolausBoost Price TargetHold$43.00 ➝ $48.00Medium
8/1/2019Piper Jaffray CompaniesBoost Price TargetOverweight$49.00 ➝ $59.00Low
8/1/2019Canaccord GenuityReiterated RatingHold$52.00Low
8/1/2019BTIG ResearchReiterated RatingBuy$52.00High
8/1/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$52.00 ➝ $57.00High
7/10/2019Needham & Company LLCReiterated RatingBuy$52.00Low
5/2/2019BTIG ResearchReiterated RatingBuy$52.00Low
5/2/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$50.00 ➝ $52.00Medium
4/2/2019Needham & Company LLCReiterated RatingBuy$50.00Low
1/31/2019BTIG ResearchReiterated RatingBuy$50.00High
1/31/2019Piper Jaffray CompaniesBoost Price TargetIn-Line ➝ Overweight$49.00High
1/31/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$48.00 ➝ $50.00High
1/14/2019Needham & Company LLCReiterated RatingBuy$48.00Low
1/7/2019Canaccord GenuityReiterated RatingHold$41.00High
1/4/2019CowenDowngradeOutperform ➝ Market Perform$38.28Medium
1/2/2019Morgan StanleyDowngradeEqual Weight ➝ Underweight$44.00 ➝ $39.00High
11/30/2018Royal Bank of CanadaBoost Price TargetSector Perform ➝ Sector Perform$40.00 ➝ $46.00Low
11/8/2018Canaccord GenuityReiterated RatingHold$43.00Low
11/8/2018Piper Jaffray CompaniesLower Price TargetOverweight$45.00N/A
10/11/2018Morgan StanleyLower Price TargetEqual Weight$47.00 ➝ $44.00Medium
10/9/2018UBS GroupInitiated CoverageNeutral ➝ Neutral$44.00Medium
9/27/2018Canaccord GenuityBoost Price TargetHold ➝ Hold$40.00 ➝ $41.00Low
9/27/2018Needham & Company LLCReiterated RatingBuy$48.00N/A
9/13/2018Canaccord GenuityLower Price TargetHold$41.00 ➝ $40.00Low
9/13/2018Bank of AmericaDowngradeBuy ➝ Neutral$47.00 ➝ $42.00High
9/5/2018BarclaysDowngradeOverweight ➝ Equal Weight$50.00 ➝ $43.00High
8/20/2018Deutsche Bank AktiengesellschaftLower Price TargetHold ➝ Hold$45.00 ➝ $43.00Low
8/14/2018Canaccord GenuityLower Price TargetHold ➝ Hold$42.00 ➝ $41.00Medium
8/13/2018Needham & Company LLCReiterated RatingBuy$48.00High
8/2/2018BTIG ResearchReiterated RatingBuy$47.00Medium
8/1/2018CowenReiterated RatingBuy$45.00Medium
8/1/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$44.00 ➝ $47.00Medium
8/1/2018Jefferies Financial GroupReiterated RatingBuy$50.00Medium
8/1/2018Deutsche Bank AktiengesellschaftBoost Price TargetHold ➝ Hold$42.00 ➝ $45.00High
8/1/2018Needham & Company LLCBoost Price TargetBuy$43.00 ➝ $48.00High
5/6/2018BTIG ResearchReiterated RatingBuy$44.00Medium
5/3/2018BarclaysLower Price TargetOverweight ➝ Overweight$54.00 ➝ $50.00High
5/3/2018Deutsche Bank AktiengesellschaftLower Price TargetHold ➝ Hold$44.00 ➝ $42.00High
5/3/2018Stifel NicolausLower Price TargetHold ➝ Hold$42.00 ➝ $40.00High
5/3/2018SVB LeerinkDowngradeOutperform ➝ Market Perform$48.00 ➝ $41.00High
5/3/2018Canaccord GenuityDowngradeBuy ➝ Hold$48.00 ➝ $39.00High
5/1/2018Needham & Company LLCReiterated RatingBuy ➝ Buy$50.00 ➝ $43.00Low
4/17/2018The Goldman Sachs GroupSet Price TargetBuy$43.00Low
3/26/2018The Goldman Sachs GroupDowngradeConviction-Buy ➝ Buy$43.00Low
2/9/2018Canaccord GenuityReiterated RatingBuy$48.00Low
2/9/2018Royal Bank of CanadaReiterated RatingHold$44.00High
2/9/2018Needham & Company LLCReiterated RatingBuy$50.00High
2/9/2018Stifel NicolausDowngradeBuy ➝ Hold$45.00 ➝ $42.00High
2/1/2018Needham & Company LLCReiterated RatingBuy$50.00Low
1/19/2018Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$49.00Medium
1/9/2018Needham & Company LLCReiterated RatingBuy ➝ Buy$48.00 ➝ $50.00Low
1/4/2018Bank of AmericaUpgradeNeutral ➝ Buy$50.00Low
1/3/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$50.00Medium
12/20/2017CowenUpgradeBuy$52.00Low
12/11/2017CowenUpgradeMarket Perform ➝ Outperform$51.00High
12/8/2017The Goldman Sachs GroupUpgradeBuy ➝ Conviction-Buy$45.00 ➝ $50.00Low
12/5/2017Needham & Company LLCReiterated RatingBuy ➝ Buy$46.00 ➝ $48.00Low
11/9/2017Piper Jaffray CompaniesReiterated RatingBuy$48.00N/A
11/3/2017Needham & Company LLCReiterated RatingBuy$50.00N/A
10/10/2017Jefferies Financial GroupReiterated RatingBuy$49.00 ➝ $44.00N/A
10/9/2017Stifel NicolausReiterated RatingBuy ➝ Buy$48.00 ➝ $45.00N/A
10/2/2017Needham & Company LLCReiterated RatingBuy$50.00Medium
9/22/2017Royal Bank of CanadaReiterated RatingHold$42.00Low
8/9/2017BarclaysReiterated RatingEqual Weight$53.00 ➝ $51.00Low
8/9/2017Royal Bank of CanadaReiterated RatingSector Perform$50.00 ➝ $45.00Low
8/3/2017BarclaysLower Price TargetOverweight$53.00 ➝ $51.00Medium
8/3/2017Deutsche Bank AktiengesellschaftLower Price TargetBuy$51.00 ➝ $49.00Medium
8/3/2017The Goldman Sachs GroupDowngradeConviction-Buy ➝ Buy$48.00 ➝ $47.00High
8/3/2017Royal Bank of CanadaLower Price TargetSector Perform ➝ Sector Perform$50.00 ➝ $45.00High
8/1/2017Needham & Company LLCReiterated RatingBuyMedium
7/21/2017Bank of AmericaReiterated RatingNeutral$44.00 ➝ $48.00Low
7/17/2017BarclaysReiterated RatingOverweight$50.00 ➝ $53.00Low
7/14/2017Piper Jaffray CompaniesReiterated RatingBuy$51.00Medium
7/14/2017Stifel NicolausReiterated RatingBuyMedium
6/28/2017Jefferies Financial GroupReiterated RatingBuy$49.00Low
5/28/2017Jefferies Financial GroupSet Price TargetBuy$49.00Low
5/14/2017BTIG ResearchReiterated RatingBuy$47.00Low
5/11/2017Stifel NicolausBoost Price TargetBuy ➝ Buy$45.00 ➝ $48.00High
5/9/2017Canaccord GenuityReiterated RatingBuy$53.00Low
4/5/2017BarclaysSet Price TargetBuy$50.00Low
4/4/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$46.00 ➝ $50.00Medium
3/30/2017SVB LeerinkReiterated RatingOutperform$52.00Low
3/14/2017Piper Jaffray CompaniesReiterated RatingOverweight$51.00Low
3/13/2017Jefferies Financial GroupReiterated RatingBuy$46.00 ➝ $49.00Low
2/15/2017Needham & Company LLCUpgradeHold ➝ Buy$46.00N/A
2/15/2017Bank of AmericaDowngradeBuy ➝ NeutralN/A
2/5/2017BTIG ResearchReiterated RatingBuy$47.00N/A
1/23/2017Canaccord GenuitySet Price TargetBuy$48.00N/A
1/18/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy$48.00N/A
1/8/2017Jefferies Financial GroupReiterated RatingBuy$46.00N/A
1/4/2017Evercore ISIDowngradeBuy ➝ Hold$42.00N/A
1/4/2017Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$44.00 ➝ $48.00N/A
12/16/2016Needham & Company LLCReiterated RatingHoldN/A
12/15/2016Canaccord GenuitySet Price TargetBuy$48.00N/A
11/19/2016BarclaysSet Price TargetBuy$45.00N/A
11/3/2016Needham & Company LLCReiterated RatingHoldN/A
11/3/2016BTIG ResearchBoost Price TargetBuy$44.00 ➝ $47.00N/A
11/3/2016BarclaysReiterated RatingBuy$45.00N/A
11/3/2016SVB LeerinkReiterated RatingTop Pick$46.00 ➝ $43.00N/A
10/15/2016Evercore ISIReiterated RatingBuy$43.00N/A
10/3/2016SVB LeerinkReiterated RatingOutperform$46.00N/A
9/23/2016BarclaysUpgradeEqual Weight ➝ Overweight$42.00 ➝ $44.00N/A
8/28/2016Piper Jaffray CompaniesSet Price TargetHold$44.00N/A
8/1/2016Royal Bank of CanadaReiterated RatingSector Perform$37.00 ➝ $39.00N/A
8/1/2016Royal Bank of CanadaBoost Price TargetSector Perform$37.00 ➝ $39.00N/A
7/31/2016BarclaysReiterated RatingEqual Weight$42.00N/A
7/28/2016Canaccord GenuitySet Price TargetBuy$45.00N/A
7/28/2016Needham & Company LLCReiterated RatingHoldN/A
7/28/2016BTIG ResearchReiterated RatingBuy$44.00N/A
7/28/2016SVB LeerinkReiterated RatingBuy$46.00N/A
7/28/2016Morgan StanleyBoost Price TargetEqual Weight$38.00 ➝ $40.00N/A
7/28/2016Jefferies Financial GroupBoost Price TargetBuy$42.00 ➝ $43.00N/A
7/28/2016Evercore ISIUpgradeHold ➝ Buy$38.00 ➝ $42.00N/A
7/25/2016Piper Jaffray CompaniesSet Price TargetHold$40.00N/A
(Data available from 7/24/2016 forward)
Hologic logo
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima quantitative viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. It has a collaboration with RadNet, Inc. to advance the use of artificial intelligence in breast health. Hologic, Inc. was founded in 1985 and is headquartered in Marlborough, Massachusetts.
Read More

Today's Range

Now: $72.30
Low: $71.57
High: $72.36

50 Day Range

MA: $65.25
Low: $60.52
High: $72.30

52 Week Range

Now: $72.30
Low: $56.81
High: $85.00

Volume

2,265,979 shs

Average Volume

2,293,703 shs

Market Capitalization

$18.53 billion

P/E Ratio

9.92

Dividend Yield

N/A

Beta

1.17

Frequently Asked Questions

What sell-side analysts currently cover shares of Hologic?

The following Wall Street research analysts have issued reports on Hologic in the last year: Argus, BTIG Research, Citigroup Inc., Evercore ISI, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Raymond James, Robert W. Baird, Smith Barney Citigroup, SVB Leerink LLC, UBS Group AG, Wells Fargo & Company, William Blair, and Zacks Investment Research.
View the latest analyst ratings for HOLX.

What is the current price target for Hologic?

14 Wall Street analysts have set twelve-month price targets for Hologic in the last year. Their average twelve-month price target is $88.00, suggesting a possible upside of 22.6%. Jefferies Financial Group Inc. has the highest price target set, predicting HOLX will reach $110.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $77.00 for Hologic in the next year.
View the latest price targets for HOLX.

What is the current consensus analyst rating for Hologic?

Hologic currently has 3 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HOLX will outperform the market and that investors should add to their positions of Hologic.
View the latest ratings for HOLX.

What other companies compete with Hologic?

How do I contact Hologic's investor relations team?

Hologic's physical mailing address is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. The medical equipment provider's listed phone number is 508-263-2900 and its investor relations email address is [email protected] The official website for Hologic is www.hologic.com.

Learn How to Analyze Your Market and Trading Plan
Custom-design an options strategy to fit your market outlook. This guide goes beyond the basics to help you understand how to evaluate a strategy’s risk and reward. Start with your market outlook, then hone in on your strategy based on the risk you’re willing to take.
pixel